Company Overview and Strategy - Azenta is uniquely positioned for strong top-line growth, margin expansion, and inorganic growth opportunities[15] - The company estimates a current serviceable addressable market (SAM) of approximately $6 billion across SMS and Multiomics[18] - Azenta's FY25 revenue was $594 million, with approximately 55% recurring revenue and 3% organic year-over-year growth[26] Sample Management Solutions (SMS) - SMS FY'25 revenue was approximately $325 million, with approximately 50% recurring revenue[85] - The SMS business has experienced a 15%+ CAGR in sample storage growth from FY'15 to FY'25[85] - The company estimates SMS has approximately 11% market share of a $3 billion serviceable addressable market[18, 88] Multiomics (GENEWIZ) - Multiomics (GENEWIZ) FY'25 revenue was approximately $269 million, with over 70% of revenue from returning customers[132] - The company estimates Multiomics has approximately 9% market share of a $3 billion serviceable addressable market[18, 137] - GENEWIZ has sequenced 15 petabytes (PB) of data and synthesized 425 million nucleotides[128] Financial Targets and Capital Allocation - The company is targeting cumulative free cash flow generation of $200 million - $250 million from FY2026 to FY2028[172] - Azenta has a $250 million share repurchase authorization[61] - The company is introducing 2028 organic financial targets including $700 million - $750 million in revenue, 6% - 8% CAGR, 70% recurring revenue, $120 million - $150 million adjusted EBITDA, and 18% - 20% adjusted EBITDA margin[186]